Search

Search Constraints

You searched for: Author/Creator Sho, Takuya

Search Results

1. Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. Issue 3 (10th August 2017)

2. Analysis of the optimal psoas muscle mass index cut‐off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Issue 6 (7th April 2020)

3. Anti‐adipogenic and antiviral effects of l‐carnitine on hepatitis C virus infection. Issue 5 (3rd October 2016)

4. Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. Issue 10 (10th July 2019)

5. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (February 2023)

6. Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. Issue 5 (11th April 2020)

7. Changes in the estimated renal function after hepatitis C virus eradication with direct‐acting antiviral agents: Impact of changes in skeletal muscle mass. Issue 5 (24th February 2021)

8. Combination of neutrophil‐to‐lymphocyte ratio and early des‐γ‐carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. Issue 6 (11th August 2016)

9. Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. Issue 2 (15th July 2020)

10. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Issue 9 (20th July 2021)